Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV (Q24202180)

1

0 references

Carlo Mengoli

2

0 references

Giovanni Serpelloni

3

0 references

Saverio G Parisi

4

0 references

Oliviero Bosco

Cochrane Database of Systematic Reviews

6

0 references

publication date

5 June 2013

0 references

published in

0 references

cites work

Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION S

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008270.PUB2